Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose ATG-Fresenius induction in kidney transplantation from non-heart-beating donors
NL-OMON30577Phase 3Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2007
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of antithymocyte globulin rabbit in delayed graft function (DGF) and acute rejection (AR) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Incidence of delayed graft function. Planned start Sep 2007; status: not yet recruiting.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
delayed graft function (DGF)acute rejection (AR)
Beyond the preview
Go deeper on NL-OMON30577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30577.